Millipore Sigma Vibrant Logo

197228 BCRP Inhibitor IV, YHO-13351 - Calbiochem

197228
가격 및 재고 조회

개요

Replacement Information

주요 사양표

Empirical Formula
C₂₆H₃₃N₃O₄S • CH₃SO₃H

가격 및 재고여부

카탈로그 번호 재고 정보패킹 포장 단위 가격(VAT 별도) 수량
197228-25MGCN
재고 정보 검색...
재고 없음재고 없음
예상 출고 가능일 
단종품
제한된 수량 가능
재고여부 확인
    Remaining: will advise
      Remaining: will advise
      추천사항
      고객 서비스로 문의
      Contact Customer Service

      Glass bottle 25 mg
      가격 검색...
      가격을 검색할 수 없습니다
      Minimum Quantity needs to be mulitiple of
      Maximum Quantity is
      가격 문의 추가 정보
      ()이 할인됨
       
      가격 문의
      Description
      OverviewAn in vivo bioavailable (~87%; t1/2 < 5 mins. during p.o. and i.v. administration) and highly water soluble ( >100 mg/ml) diethylaminoacetate prodrug of YHO-13177 (Cat. No. 197227) that reverses BCRP-mediated irinotecan resistance in P388/BCRP and HCT116/BCRP xenograft mouse models, and suppresses tumor growth and significantly enhances the survival (100 or 200 mg/kg, i.p.).
      Catalogue Number197228
      Brand Family Calbiochem®
      SynonymsDiethylaminoacetic acid, 1-(5-((Z)-2-cyano-2- (3,4-dimethoxyphenyl)vinyl)thiophen-2-yl)piperidin-4-yl ester, Methanesulfonate
      References
      ReferencesYamazaki, R., et al. 2011. Mol. Cancer Ther. 10, 1252.
      Product Information
      FormYellow solid
      Hill FormulaC₂₆H₃₃N₃O₄S • CH₃SO₃H
      Chemical formulaC₂₆H₃₃N₃O₄S • CH₃SO₃H
      Hygroscopic Hygroscopic
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Purity≥97% by HPLC
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Shipped at Ambient Temperature or with Blue Ice or with Dry Ice
      Toxicity Standard Handling
      Storage -20°C
      Protect from Light Protect from light
      Hygroscopic Hygroscopic
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications

      Documentation

      BCRP Inhibitor IV, YHO-13351 - Calbiochem MSDS

      타이틀

      물질안전보건자료(MSDS) 

      BCRP Inhibitor IV, YHO-13351 - Calbiochem Certificates of Analysis

      TitleLot Number
      197228

      References

      참고문헌 보기
      Yamazaki, R., et al. 2011. Mol. Cancer Ther. 10, 1252.
      Data Sheet

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision28-September-2012 JSW
      SynonymsDiethylaminoacetic acid, 1-(5-((Z)-2-cyano-2- (3,4-dimethoxyphenyl)vinyl)thiophen-2-yl)piperidin-4-yl ester, Methanesulfonate
      DescriptionAn in vivo bioavailable (~87%; t1/2 < 5 mins. during p.o. and i.v. administration) and highly water soluble ( >100 mg/ml) diethylaminoacetate prodrug of YHO-13177 (Cat. No. 197227) that reverses BCRP-mediated irinotecan resistance in P388/BCRP and HCT116/BCRP xenograft mouse models, and suppresses tumor growth and significantly enhances the survival (100 or 200 mg/kg, i.p.).
      FormYellow solid
      Intert gas (Yes/No) Packaged under inert gas
      Chemical formulaC₂₆H₃₃N₃O₄S • CH₃SO₃H
      Structure formulaStructure formula
      Purity≥97% by HPLC
      SolubilityH₂O (25 mg/ml)
      Storage -20°C
      Hygroscopic
      Protect from light
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
      Toxicity Standard Handling
      ReferencesYamazaki, R., et al. 2011. Mol. Cancer Ther. 10, 1252.